Strengthening FTCA Risk Assessments: Addressing Common Deficiencies for 2026 Compliance In response to 2026 FTCA deeming application reviews, the FTCA Division of HRSA has issued a series of warning notices...
Stronger Together: Merger and Acquisition Strategies and the HRSA Successor-in-Interest Process As health centers respond to financial pressures, seek economies of scale, and aim to expand the reach and scope...
This session will distill HRSA’s sliding fee discount program and billing/collections requirements into practical steps your team can apply—income verification, discount schedules, nominal fees, hardship processes, and patient communications. Participants...
Did you know that HRSA recently announced updates affecting the Operational Site Visit (OSV) process and the Site Visit Protocol, including developments that influence how health centers demonstrate compliance? Key...
Is your health center’s website included in your 2026 Compliance Work Plan? It should be. With the compliance date approaching for new website accessibility requirements under Section 504 of the...
The federal 340B drug discount program has undergone substantial changes in recent years, with new challenges brought on by manufacturer restrictions and diminishing reimbursement counterbalanced by new opportunities. Perhaps one...
Powers Pyles Sutter & Verville PC
1250 Connecticut Ave, NW
Eighth Floor
Washington DC 20036
Tel: (202) 466-6550
Fax: (202) 792-6540
Email: info@powerslaw.com
© Powers Pyles Sutter and Verville PC 2026. All rights reserved. 1250 Connecticut Ave NW | Eighth Floor | Washington, DC 20036 | 202.466.6550 | Fax 202.792.6540 Web Design by Orpheus, Inc.
